Engrail Therapeutics Funding: $220M Raised, Series B (2024)

Engrail Therapeutics is a Biotech company. It has raised $220M in total funding. Latest round: Series B. Backed by Norwest.

Engrail Therapeutics funding overview

Engrail Therapeutics is a Biotech company. Engrail Therapeutics has raised $220M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in January 2024. The round record for Engrail Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Norwest.

Engrail Therapeutics at a glance

Total raised
$220M
Latest round
Series B
Latest round date
January 2024
Industry
Biotech
Notable investors
Norwest

Frequently asked about Engrail Therapeutics funding

How much has Engrail Therapeutics raised?
Engrail Therapeutics has raised $220M in total disclosed funding across the rounds on record.
Who has invested in Engrail Therapeutics?
Norwest are named among the investors backing Engrail Therapeutics.
What was the latest Engrail Therapeutics funding round?
The most recent disclosed round is a Series B, announced in January 2024.
Where is Engrail Therapeutics based?
No headquarters location is disclosed for Engrail Therapeutics.
What sector does Engrail Therapeutics operate in?
Engrail Therapeutics is tracked under Biotech, with $220M in disclosed funding.
When did Engrail Therapeutics last raise?
The last disclosed Engrail Therapeutics round closed in January 2024 at Series B.

Every Engrail Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies at a similar stage.

Engrail Therapeutics founders (1)

Companies related to Engrail Therapeutics (36)

Browse related funding lists (4)

Company funding database · Investor directory · Founder database · Mega-rounds 2026